China's MOFCOM Promises Increased Scrutiny Over M&A In 2012
This article was originally published in PharmAsia News
China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.
You may also be interested in...
HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups
[Editor's note: This is part two of a two-part feature; part one covered the background of China's National Development and Reform Commission charge against consumer goods company Unilever and what multinational companies operating in China should take away from the incident. This second part looks at the larger impact of China's inflation on pharma companies.]
HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law